RxDoctor Payments Data

Thomas Hurst, MD

Endocrinology, Diabetes & Metabolism · Cincinnati, OHNPI 1134576960

Payments from drug & device makers

$967in general payments, 2019–2025

Across 29 payments — averaging $33.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$235
  • Abbott$148
  • BETA Bionics, Inc.$139
  • Sequel Med Tech, LLC$138
  • AstraZeneca$113
  • Lilly USA, LLC$53
  • plus $143 from 7 others

What the payments were for

  • Food & beverage$95599%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$967 in reported general payments places this provider in the 40th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

See all endocrinology, diabetes & metabolism providers in Ohio

Medicare billing

Part B allowed, 2024
$149,750
Medicare patients
211
Services billed
9,347

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide259$354,849
MounjaroTirzepatide156$182,857
TrulicityDulaglutide148$157,457
JardianceEmpagliflozin141$144,160
Humulin R U-500 KwikpenInsulin Regular, Human29$68,905
TymlosAbaloparatide22$58,076
Tresiba Flextouch U-200Insulin Degludec57$55,577
FarxigaDapagliflozin Propanediol53$48,419
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog46$33,969
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/727$32,291
Fiasp FlextouchInsulin Aspart (Niacinamide)38$30,445
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog35$27,908
Tresiba Flextouch U-100Insulin Degludec40$24,172
Humalog Kwikpen U-100Insulin Lispro57$21,227
Humalog Kwikpen U-200Insulin Lispro12$20,222

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$45$354,849259 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$53$344,402321 claims
Boehringer IngelheimJardiance$18$144,160141 claims
AstraZenecaFarxiga$113$48,41953 claims
Sanofi-aventis U.S. LLCLantus$14$2,70620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

Other endocrinology, diabetes & metabolism in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →